Do analysts prefer DARE or TNFA?

Dare Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 407.61%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Dare Bioscience is more favorable than TNF Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DARE or TNFA more profitable?

Dare Bioscience's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% TNF Pharmaceuticals N/A -69.21% -33.98%

Do analysts prefer TNFA or SKYE?

Skye Bioscience has a consensus price target of $9.80, indicating a potential upside of 1,172.73%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than TNF Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Which has stronger earnings & valuation, TNFA or SKYE?

Skye Bioscience is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is TNFA or SKYE more profitable?

TNF Pharmaceuticals' return on equity of -69.21% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets TNF Pharmaceuticals N/A -69.21% -33.98% Skye Bioscience N/A -217.27% -162.39%

Do analysts recommend CRVO or TNFA?

CervoMed currently has a consensus price target of $22.60, indicating a potential upside of 788.02%. Given CervoMed's stronger consensus rating and higher possible upside, research analysts clearly believe CervoMed is more favorable than TNF Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CRVO or TNFA?

In the previous week, CervoMed had 7 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 8 mentions for CervoMed and 1 mentions for TNF Pharmaceuticals. CervoMed's average media sentiment score of 0.35 beat TNF Pharmaceuticals' score of 0.00 indicating that CervoMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral TNF Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BCTX or TNFA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, BCTX or TNFA?

Briacell Therap is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$23.33 N/A TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A

Is BCTX or TNFA more profitable?

TNF Pharmaceuticals' return on equity of -69.21% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% TNF Pharmaceuticals N/A -69.21% -33.98%

Does the media prefer BCTX or TNFA?

In the previous week, Briacell Therap had 3 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 4 mentions for Briacell Therap and 1 mentions for TNF Pharmaceuticals. Briacell Therap's average media sentiment score of 0.75 beat TNF Pharmaceuticals' score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TNF Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TNFA or KYNB?

Kyntra Bio has a consensus target price of $30.00, indicating a potential upside of 322.24%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than TNF Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media refer more to TNFA or KYNB?

In the previous week, Kyntra Bio had 4 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 5 mentions for Kyntra Bio and 1 mentions for TNF Pharmaceuticals. Kyntra Bio's average media sentiment score of 0.70 beat TNF Pharmaceuticals' score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TNF Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyntra Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TNF Pharmaceuticals (TNFA) Competitors

$3.87 +0.05 (+1.31%)

As of 06/12/2026

Compare

TNFA vs. DARE, SKYE, CRVO, BCTX, and KYNB

Should you buy TNF Pharmaceuticals stock or one of its competitors? MarketBeat compares TNF Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TNF Pharmaceuticals include Dare Bioscience (DARE), Skye Bioscience (SKYE), CervoMed (CRVO), Briacell Therap (BCTX), and Kyntra Bio (KYNB). These companies are all part of the "pharmaceutical products" industry.

How does TNF Pharmaceuticals compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Dare Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 407.61%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Dare Bioscience is more favorable than TNF Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dare Bioscience has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

In the previous week, Dare Bioscience and Dare Bioscience both had 1 articles in the media. Dare Bioscience's average media sentiment score of 1.89 beat TNF Pharmaceuticals' score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Dare Bioscience	Very Positive
TNF Pharmaceuticals	Neutral

Dare Bioscience has higher revenue and earnings than TNF Pharmaceuticals. Dare Bioscience is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	28.65	-$13.40M	-$0.95	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dare Bioscience's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Summary

Dare Bioscience beats TNF Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Skye Bioscience?

TNF Pharmaceuticals (NASDAQ:TNFA) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Skye Bioscience has a consensus price target of $9.80, indicating a potential upside of 1,172.73%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than TNF Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

In the previous week, TNF Pharmaceuticals and TNF Pharmaceuticals both had 1 articles in the media. Skye Bioscience's average media sentiment score of 1.87 beat TNF Pharmaceuticals' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
TNF Pharmaceuticals	Neutral
Skye Bioscience	Very Positive

TNF Pharmaceuticals' return on equity of -69.21% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
Skye Bioscience	N/A	-217.27%	-162.39%

9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 0.5% of TNF Pharmaceuticals shares are held by insiders. Comparatively, 6.2% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Skye Bioscience is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.95, indicating that its share price is 195% more volatile than the broader market.

Summary

Skye Bioscience beats TNF Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to CervoMed?

CervoMed (NASDAQ:CRVO) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

25.2% of CervoMed shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 35.8% of CervoMed shares are held by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TNF Pharmaceuticals has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	5.88	-$26.97M	-$3.28	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

TNF Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. TNF Pharmaceuticals' return on equity of -69.21% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

CervoMed currently has a consensus price target of $22.60, indicating a potential upside of 788.02%. Given CervoMed's stronger consensus rating and higher possible upside, research analysts clearly believe CervoMed is more favorable than TNF Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CervoMed has a beta of -0.68, meaning that its stock price is 168% less volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

In the previous week, CervoMed had 7 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 8 mentions for CervoMed and 1 mentions for TNF Pharmaceuticals. CervoMed's average media sentiment score of 0.35 beat TNF Pharmaceuticals' score of 0.00 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
TNF Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CervoMed beats TNF Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Briacell Therap has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Briacell Therap is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TNF Pharmaceuticals' return on equity of -69.21% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

In the previous week, Briacell Therap had 3 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 4 mentions for Briacell Therap and 1 mentions for TNF Pharmaceuticals. Briacell Therap's average media sentiment score of 0.75 beat TNF Pharmaceuticals' score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TNF Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Briacell Therap and TNF Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Kyntra Bio?

TNF Pharmaceuticals (NASDAQ:TNFA) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kyntra Bio has a consensus target price of $30.00, indicating a potential upside of 322.24%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than TNF Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Kyntra Bio has a net margin of 2,199.13% compared to TNF Pharmaceuticals' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
Kyntra Bio	2,199.13%	N/A	-36.71%

In the previous week, Kyntra Bio had 4 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 5 mentions for Kyntra Bio and 1 mentions for TNF Pharmaceuticals. Kyntra Bio's average media sentiment score of 0.70 beat TNF Pharmaceuticals' score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TNF Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio has higher revenue and earnings than TNF Pharmaceuticals. TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A
Kyntra Bio	$6.44M	4.47	$183.45M	$40.46	0.18

TNF Pharmaceuticals has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

Summary

Kyntra Bio beats TNF Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

Get TNF Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNFA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNFA vs. The Competition

Export

Metric	TNF Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.15M	$2.99B	$6.50B	$12.37B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-0.02	18.58	24.01	24.71
Price / Sales	N/A	468.49	540.55	165.59
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.01	4.03	10.55	6.85
Net Income	-$23.36M	$75.79M	$3.56B	$337.45M
7 Day Performance	4.31%	2.68%	1.54%	2.70%
1 Month Performance	-24.56%	0.37%	2.48%	4.60%
1 Year Performance	-71.75%	24.51%	26.49%	32.81%

TNF Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNFA TNF Pharmaceuticals	0.0227 of 5 stars	$3.87 +1.3%	N/A	-71.8%	$7.15M	N/A	N/A	6
DARE Dare Bioscience	2.4164 of 5 stars	$1.92 +3.8%	$10.00 +420.8%	-33.3%	$27.71M	$1.03M	N/A	30	Positive News
SKYE Skye Bioscience	2.6598 of 5 stars	$0.75 -2.5%	$9.80 +1,205.1%	-61.7%	$27.06M	N/A	N/A	11	Positive News
CRVO CervoMed	3.9488 of 5 stars	$2.89 -0.7%	$22.60 +682.0%	-65.6%	$26.94M	$4.01M	N/A	4	Gap Up
BCTX Briacell Therap	0.5249 of 5 stars	$3.07 -0.6%	N/A	-91.1%	$26.88M	N/A	N/A	8	Earnings Report Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNFA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TNF Pharmaceuticals (TNFA) Competitors

TNFA vs. DARE, SKYE, CRVO, BCTX, and KYNB

How does TNF Pharmaceuticals compare to Dare Bioscience?

Summary

How does TNF Pharmaceuticals compare to Skye Bioscience?

Summary

How does TNF Pharmaceuticals compare to CervoMed?

Summary

How does TNF Pharmaceuticals compare to Briacell Therap?

Summary

How does TNF Pharmaceuticals compare to Kyntra Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA vs. The Competition

TNF Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TNF Pharmaceuticals (TNFA) Competitors

TNFA vs. DARE, SKYE, CRVO, BCTX, and KYNB

How does TNF Pharmaceuticals compare to Dare Bioscience?

Do analysts prefer DARE or TNFA?

Which has more volatility and risk, DARE or TNFA?

Does the media refer more to DARE or TNFA?

Which has better valuation and earnings, DARE or TNFA?

Do insiders & institutionals believe in DARE or TNFA?

Is DARE or TNFA more profitable?

Summary

How does TNF Pharmaceuticals compare to Skye Bioscience?

Do analysts prefer TNFA or SKYE?

Does the media prefer TNFA or SKYE?

Is TNFA or SKYE more profitable?

Do institutionals and insiders have more ownership in TNFA or SKYE?

Which has stronger earnings & valuation, TNFA or SKYE?

Which has more volatility & risk, TNFA or SKYE?

Summary

How does TNF Pharmaceuticals compare to CervoMed?

Do insiders & institutionals have more ownership in CRVO or TNFA?

Which has preferable valuation & earnings, CRVO or TNFA?

Is CRVO or TNFA more profitable?

Do analysts recommend CRVO or TNFA?

Which has more volatility & risk, CRVO or TNFA?

Does the media favor CRVO or TNFA?

Summary

How does TNF Pharmaceuticals compare to Briacell Therap?

Which has more risk and volatility, BCTX or TNFA?

Which has stronger valuation & earnings, BCTX or TNFA?

Do analysts recommend BCTX or TNFA?

Is BCTX or TNFA more profitable?

Does the media prefer BCTX or TNFA?

Do insiders & institutionals have more ownership in BCTX or TNFA?

Summary

How does TNF Pharmaceuticals compare to Kyntra Bio?

Do insiders and institutionals believe in TNFA or KYNB?

Do analysts recommend TNFA or KYNB?

Is TNFA or KYNB more profitable?

Does the media refer more to TNFA or KYNB?

Which has better earnings and valuation, TNFA or KYNB?

Which has more volatility and risk, TNFA or KYNB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA vs. The Competition

TNF Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools